The efficacy and safety profile of anlotinib plus docetaxel as second-line treatment in advanced non-small cell lung cancer.
JOURNAL OF CLINICAL ONCOLOGY（2021）
关键词
anlotinib,lung cancer,docetaxel,second-line,non-small
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要